| Aug 25, 2026 | Xiaobin Wu | PRESIDENT AND COO | SELL | 280.000 | $380.00 | $106K |
| Aug 11, 2026 | Henry Chan Lee | SVP, GENERAL COUNSEL | SELL-OPTIONS | — | $275.68 | $450K |
| Aug 10, 2026 | JOHN OYLER | CHIEF EXECUTIVE OFFICER | SELL | 240.810K | $359.12 | $86.5M |
| Aug 3, 2026 | Aaron Rosenberg | CHIEF FINANCIAL OFFICER | SELL | 1.157K | $312.71 | $362K |
| Jul 30, 2026 | Chan Henry Lee | SVP, GENERAL COUNSEL | SELL | 1.044K | $323.69 | $338K |
| Jul 22, 2026 | Chan Henry Lee | SVP, GENERAL COUNSEL | SELL-OPTIONS | — | $258.29 | $223K |
| Jul 20, 2026 | JOHN OYLER | CHIEF EXECUTIVE OFFICER | SELL | 75.723K | $217.62 | $30.5M |
| Jul 17, 2026 | JOHN OYLER | CHIEF EXECUTIVE OFFICER | SELL-OPTIONS | — | $215.98 | $12.4M |
| Jul 15, 2026 | JOHN OYLER | CHIEF EXECUTIVE OFFICER | SELL-OPTIONS | — | $230.42 | $48.2M |
| Jul 14, 2026 | JOHN OYLER | CHIEF EXECUTIVE OFFICER | SELL | 12.261K | $180.01 | $37.4M |
| Jul 10, 2026 | JOHN OYLER | CHIEF EXECUTIVE OFFICER | SELL-OPTIONS | — | $170.04 | $16.0M |
| Jul 8, 2026 | Chan Henry Lee | SVP, GENERAL COUNSEL | SELL-OPTIONS | — | $247.01 | $74K |
| Jun 23, 2026 | Xiaobin Wu | PRESIDENT AND COO | SELL | 1.292K | $276.26 | $357K |
| Jun 23, 2026 | JOHN OYLER | CHIEF EXECUTIVE OFFICER | SELL | 3.410K | $273.78 | $934K |
| Jun 23, 2026 | Lai Wang | PRESIDENT, GLOBAL HEAD R&D | SELL | 1.068K | $276.74 | $296K |
| Jun 16, 2026 | Xiaobin Wu | PRESIDENT AND COO | SELL | 1.357K | $266.76 | $362K |
| Jun 16, 2026 | JOHN OYLER | CHIEF EXECUTIVE OFFICER | SELL | 3.693K | $265.55 | $981K |
| Jun 16, 2026 | Henry Chan Lee | SVP, GENERAL COUNSEL | SELL | 590.000 | $265.98 | $157K |
| Jun 16, 2026 | Lai Wang | PRESIDENT, GLOBAL HEAD R&D | SELL | 1.169K | $265.39 | $310K |
| Jun 11, 2026 | Titus Ball | PRINCIPAL ACCOUNTING OFFICER | GRANT | 31.044K | $257.20 | $43K |
| Jun 11, 2026 | Lai Wang | PRESIDENT, GLOBAL HEAD R&D | GRANT | 117.869K | $261.00 | $197K |
| Jun 11, 2026 | Aaron Rosenberg | CHIEF FINANCIAL OFFICER | GRANT | 70.544K | $257.74 | $163K |
| Jun 11, 2026 | Xiaobin Wu | PRESIDENT AND COO | GRANT | 117.999K | $261.20 | $164K |
| Jun 11, 2026 | Henry Chan Lee | SVP, GENERAL COUNSEL | GRANT | 44.643K | $257.63 | $110K |
| Jun 11, 2026 | JOHN OYLER | CHIEF EXECUTIVE OFFICER | GRANT | 175.982K | $257.24 | $501K |
| Jun 8, 2026 | Titus Ball | PRINCIPAL ACCOUNTING OFFICER | SELL | 136.000 | $271.33 | $37K |
| Jun 8, 2026 | Henry Chan Lee | SVP, GENERAL COUNSEL | SELL | 871.000 | $270.42 | $236K |
| Jun 8, 2026 | Lai Wang | PRESIDENT, GLOBAL HEAD R&D | SELL | 1.367K | $269.38 | $368K |
| Jun 8, 2026 | Xiaobin Wu | PRESIDENT AND COO | SELL | 1.484K | $269.37 | $400K |
| Jun 8, 2026 | JOHN OYLER | CHIEF EXECUTIVE OFFICER | SELL | 4.940K | $270.56 | $1.3M |
| Jun 1, 2026 | Qingqing Yi | DIRECTOR | SELL | 235.000 | $279.13 | $66K |
| May 22, 2026 | Alessandro Riva | DIRECTOR | SELL | 212.000 | $309.51 | $66K |
| May 22, 2026 | Margaret Dugan | DIRECTOR | SELL | 212.000 | $309.60 | $66K |
| May 22, 2026 | Corsee Corazon Sanders | DIRECTOR | SELL | 212.000 | $309.59 | $66K |
| May 22, 2026 | BAKER BROS ADVISORS LP, LP, Baker Bros Advisors GP LLC, Baker Brothers Life Sciences LP, FELIX BAKER, JULIAN BAKER | — | SELL | 10.998K | $23.82 | $262K |
| May 13, 2026 | Henry Chan Lee | SVP, GENERAL COUNSEL | SELL-OPTIONS | — | $251.14 | $40K |
| Apr 8, 2026 | Henry Chan Lee | SVP, GENERAL COUNSEL | SELL-OPTIONS | — | $251.58 | $40K |
| Mar 11, 2026 | Henry Chan Lee | SVP, GENERAL COUNSEL | SELL-OPTIONS | — | $245.82 | $37K |
